Douglass Winthrop Advisors, LLC Salarius Pharmaceuticals, Inc. Transaction History

Douglass Winthrop Advisors, LLC

  • $4.72 Billion
  • Q1 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 02, 2021
SELL
$1.02 - $1.52 $80,382 - $119,785
-78,806 Closed
0 $0
Q3 2019

Oct 08, 2019
BUY
$5.28 - $20.25 $416,095 - $1.6 Million
78,806 New
78,806 $429,000

About Salarius Pharmaceuticals, Inc.

SLRX Quotes by TradingView
  • Ticker SLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,244,650
  • Market Cap $4.11M
  • Description
  • Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...
More about SLRX
Track This Portfolio

Track Douglass Winthrop Advisors, LLC Portfolio

Follow Douglass Winthrop Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Douglass Winthrop Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Douglass Winthrop Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email